<DOC>
	<DOCNO>NCT00987506</DOCNO>
	<brief_summary>The objective study prepare element response Haute Autorité de Santé ( High Health Authority ) France , expect data relate routine use XIENCE V® endoprothesis within 5 year follow marketing .</brief_summary>
	<brief_title>Evaluation XIENCE V® Endoprothesis Used Coronary Angioplasty , LPPR ( List Reimbursable Products Services ) Indications Patients Monitored 2 Years France</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>All patient enrol study must : least 18 ; cover Social Security agree enrol study ( sign inform consent read information letter ) . In addition , Xience V endoprothesis implantation must perform follow LPPR indication : Treatment coronary heart disease attributable de novo lesion ( reference vessel 2.5 3.5 mm ) native coronary artery , solely follow group patient : patient diabetes ; lesion small vessel ( diameter &lt; 3 mm ) ; long lesion ( long 15 mm ) ; stenosis proximal anterior intraventricular septum . The use Xience V stent limit one per patient , except : case acute occlusive dissection three stent , maximum , may cover ; pluritroncular diabetic patient , case bypass contraindicate : stent per artery , limit three per patient , may cover . Pregnant woman Patients : non cardiac vital prognosis endanger year follow implantation ; le 72 hour myocardial infarction ; low leave ventricular ejection fraction &lt; 30 % ; allergy platelet antiaggregant treatment , heparin , chrome cobalt alloy , angiography contrast medium ; stenosis unprotected common trunk ; lesion calcification predilated ; thrombus detect angiography lesion treat ; intrastent restenosis . Are also exclude : patient angioplasty implantation endoprothesis vessel ; patient angioplasty implantation endoprothesis 6 previous month ; Patients unable keep treatment associate aspirin thiénopyridines least 6 month ; Patients reside abroad monitor accord modality study ; Patients unable give free inform consent ; On hand , absence clinical validation , subgroup risk patient ( notably bifurcation lesion pluritroncular lesion ) consider , take alone , indication use Xience V .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>drug elute stent</keyword>
	<keyword>Stents</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Chronic coronary occlusion</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>Vascular disease</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Coronary artery stenosis</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Restenosis</keyword>
</DOC>